At a glance
ClinicalIndex Comparison RecordPhase 2Active· 33 enrolled
Drug / intervention
Enoblituzumabdrug
Likely dose
Enoblituzumab 15mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate- and High-Risk Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Oct 4, 2016·Updated Jul 22, 2025
In Brief
A Phase 2 clinical trial evaluating Enoblituzumab for Prostate Cancer. Active but no longer recruiting, targeting 33 participants across 1 site.
Detailed Summary
This study evaluates the safety, anti-tumor effect, and immunogenicity of Enoblituzumab given before radical prostatectomy. All patients will receive Enoblituzumab for 6 weekly doses beginning 50 days prior to radical prostatectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsMacroGenics
Timeline
Phase 2ActiveOverdue
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartFeb 2017
Primary CompletionAug 2020
Study CompletionJul 2026
TodayJul 2026
First PostedOct 4, 2016
Enrollment StartFeb 14, 2017
Primary CompletionAug 11, 2020
Study CompletionJul 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 9.7 years ago
Interventions
Enoblituzumabdrug
Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.